VivoSeq
Other

Vasovagal Syncope

12

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Vasovagal syncope is an emerging landscape with 12 programs across 8 companies. The most active players are Exela Pharma Sciences, LLC., Map77, Novartis. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

80/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Exela Pharma Sciences, LLC.

1 program

Phase 1M

Map77

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Takeda logo

Takeda

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

12

clinical trials

Completed4 · 33%
Active, not recruiting3 · 25%
Recruiting3 · 25%
Unknown status1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Treatment Strategy of Vasovagal Syncope
Recruiting·CChina National Center for Cardiovascular Diseases·N/A·NCT05803148·184 enrolled
A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)
Recruiting·UUniversity of Calgary·Phase 2·NCT05755737·70 enrolled
Study of Atomoxetine in the Prevention of Vasovagal Syncope
Recruiting·UUniversity of Calgary·Phase 3·NCT05159687·180 enrolled
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV
Active, not recruiting·—·Phase 4·NCT01456481·134 enrolled
Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Active, not recruiting·UUniversity of Calgary·Phase 4·NCT02123056·52 enrolled
A New Red Flag Classification to Predict Vasovagal Event During Office Hysteroscopy: A Prospective Feasibility Study
Active, not recruiting·Tanvir Hospital·N/A·NCT07030218·100 enrolled
Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Completed·UUniversity of Calgary·Phase 2·NCT02500732·57 enrolled
Clinical Trial for the Prevention of Vasovagal Syncope
Completed·UUniversity of Calgary·Phase 4·NCT00118482·213 enrolled
Mechanisms of Vasovagal Syncope
Completed·NNew York Medical College·Phase 1·NCT01791816·90 enrolled
The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT04972123·143 enrolled
Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)
Terminated·NNew York Medical College·Phase 2·NCT02558972·30 enrolled
Midodrine and Fludrocortisone for Vasovagal Syncope
Unknown status·TTehran Heart Center·Phase 3·NCT04595942·1,375 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)